Poolbeg Pharma PLC (AIM:POLB) chief executive Jeremy Skillington joins Proactive London’s Katie Pilbeam to talk about their deal with testing and support specialist, Eurofins Genomics.
The partnership is to complete the next-generation RNA sequencing of respiratory syncytial virus (RSV) disease progression samples from human viral challenge studies.
The project with Eurofins is expected to be completed by the end of 2021.
source